Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04523168 · ClinicalTrials.gov registry record · NA

Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction

A NA study of Coronary Microvascular Dysfunction, sponsored by Amir Lerman.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT04523168 is a NA study of Coronary Microvascular Dysfunction that has completed, run by Amir Lerman. The registered enrollment target is 30 participants, below the 268-participant average among 7 other Coronary Microvascular Dysfunction trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04523168, a NA study of Coronary Microvascular Dysfunction, has completed, sponsored by Amir Lerman.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study is being done to evaluate the role of a novel implantable device, called The Neovasc Reducer™ System, in improving microvascular function, symptoms and quality of life in symptomatic patients with coronary microvascular dysfunction.

Interventions

  • DEVICE The Neovasc Reducer™ System

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-06-28
Est. Completion 2023-07-28
Phase NA

Sponsor

Amir Lerman

1 total trials

What the Registry Record Tells You About NCT04523168

The ClinicalTrials.gov registry entry for NCT04523168 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 7 other Coronary Microvascular Dysfunction trials with a reported enrollment target (89% lower). The listed sponsor is Amir Lerman, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Microvascular Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which The Neovasc Reducer™ System is the first listed.

NCT04523168 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04523168 about?

NCT04523168 is a clinical study titled "Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction". This study is being done to evaluate the role of a novel implantable device, called The Neovasc Reducer™ System, in improving microvascular function, symptoms and quality of life in symptomatic patients with coronary microvascular dysfunction.

What is the current status of trial NCT04523168?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-06-28. Estimated completion is 2023-07-28.

What conditions does trial NCT04523168 study?

This clinical trial studies the following conditions: Coronary Microvascular Dysfunction.

What interventions are being tested in trial NCT04523168?

The interventions under investigation include: The Neovasc Reducer™ System (DEVICE).

Who is sponsoring clinical trial NCT04523168?

This trial is sponsored by Amir Lerman, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04523168 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Microvascular Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.